Vaxart, Inc. (VXRT)
|Net Income (ttm)||-63.57M|
|Day's Range||6.09 - 6.64|
|52-Week Range||4.86 - 24.90|
|Price Target||13.00 (+98.2%)|
|Earnings Date||Nov 11, 2021|
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, wh... [Read more...]
Financial PerformanceFinancial Statements
According to 3 analysts, the average rating for Vaxart stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 98.17% from the latest price.
The initial data on omicron suggests that the pandemic has entered a new, less deadly phase.
Despite a new factory acquisition, VXRT stock is down 9% on the day as 'Mad Money' host Jim Cramer warns investors about Vaxart. The post VXRT Stock: Other Vaccine Stocks Are Gaining But Jim Cramer Just...
Purchase expected to give Vaxart greater control over manufacturing schedules Purchase expected to give Vaxart greater control over manufacturing schedules
Vaxart Inc. (NASDAQ:VXRT) shares were trading higher Monday. A company executive will present an overview of the company's COVID-19 oral vaccine candidate at the World Vaccine & Immunotherapy Congress o...
Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Wednesday. The company announced that an executive will present an overview of the company's COVID-19 oral vaccine candidate at the World Vaccine & I...
Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine...
A new Stanford study published in Cell Host and Microbe finds that protection against influenza infection may be achieved through mechanisms other than the development of serum antibodies A new Stanford...
Vaxart Inc. (NASDAQ:VXRT) shares are trading higher Thursday after bouncing off support. There looks to be no company evident news to explain the jump in price.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer, and ...
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 6.67% and -9.91%, respectively, for the quarter ended September 2021.
VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing
Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced that it has dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial, th...
VXRT stock is still worth a shot, as there's still big potential demand for a "no-needle" Covid-19 vaccine alternative. The post Don't Write Off Vaxart, As Its Oral Vaccine Still Has a Chance appeared f...
This biotech has a nifty trick potentially up its sleeve.
Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine Covaxin, for children between the ages of 2 and 18. Ocugen is partnere...
The company is working on a vaccine candidate that doesn't involve a needle.
Vaxart Inc (NASDAQ: VXRT) is trading higher Friday after the company reported a Duke University-led study published in bioRxiv showed that the company's investigational oral tablet vaccine reduced the a...
Thursday's gains could be just the beginning.
Vaxart Inc (NASDAQ: VXRT) is surging higher in after-hours trading Thursday after the company reported a Duke University-led study published in bioRxiv showed that the company's investigational oral tab...
New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SA...
SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 /PRNewswire/ -- A Duke University-led study published in bioRxiv showed that Vaxart, Inc.'s (NASDAQ: VXRT) investigational oral tablet vaccine reduced the airbo...
Vaxart (VXRT) commences recruiting subjects in its mid-stage study for its oral vaccine tablet for COVID-19. It will begin dosing in the United States later this month.
A COVID-19 antiviral pill may undermine the biotech's value proposition.